Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Azacitidine combined with Venetoclax for pre-emptive treatment of AML/MDS after allogeneic stem cell transplantation: A prospective phase II study

View Full Paper
Ask AI
Bookmark
Share

Authors

LLLizhen LiuXLXiaoyu LaiLYLuxin Yang

Discussion

Loading...

Member takes

Overview

Prospective phase II study reveals venetoclax-based treatment improves progression-free survival in AML patients after allogeneic stem cell transplantation.

Key Points

  • Pre-emptive treatment improved major response rates, with 67.4% by the third treatment cycle, sustaining efficacy.
  • Among 44 patients, major responses were seen in 67.4%, leading to a significant reduction in relapse risk post-transplantation.
  • Patients received MRD-guided therapy comprising azacitidine and venetoclax administered every 4-8 weeks for up to 6 cycles.
  • Over two years, overall survival was 73.5% and progression-free survival reached 48.6%, indicating a need for further studies for long-term outcomes.

Cite This Study

Liu et al. (2025) studied this question.

synapsesocial.com/papers/69362f4b4fa91c937236d76chttps://doi.org/10.1182/blood-2025-1061
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A pre-emptive bridge-to-transplant therapy for measurable residual disease with venetoclax and azacitidine in NPM1-mutated Acute Myeloid Leukemia: Updates from the ongoing GIMEMA AML2521 phase 2 trial2025
  2. 2A phase I/II trial of azacitidine and venetoclax in previously untreated Myelodysplastic Syndromes2025 · 1 citations
  3. 3The venetoclax combined with metronomic low-dose decitabine and interferon for preventing post-transplant relapse in high-risk MDS and AML patients2025
  4. 4Phase II trial of venetoclax in combination with azacitidine as maintenance therapy for high-risk acute leukemia following allogeneic stem cell transplantation2025
  5. 5Phase II study of clinical efficacy of venetoclax in combination with azacitidine in patients with therapy related myelodysplastic syndrome (t-MDS)2025